Allotype BioDiscovery is a specialist provider of Olink® proteomics services, supporting researchers in both academia and the biopharma industry with high-quality, reliable data to drive biomarker discovery and drug development.
Our journey began in 2012 as the Leeds Immunogenomics Facility (now knows as Leeds Translational and Biomarker Facility), created to provide a sustainable funding model for skilled technical staff. As demand grew, so did our capabilities – expanding beyond our original scope to offer a broader range of services in proteomics and translational medicine.
With support from the University of Leeds Research & Innovation Service (RIS), we transitioned into Allotype BioDiscovery to better serve the growing needs of the biopharma sector. This funding allowed us to open a dedicated laboratory within Nexus, the University’s innovation hub that connects research with industry, giving us a modern, dedicated space to deliver our services more efficiently.
We are proud to be the first and most experienced UK facility certified to run Olink® panels, and we maintain robust quality management to ensure every project meets the highest scientific standards.
At Allotype BioDiscovery, we combine technical expertise with a collaborative mindset – working closely with our clients to turn complex data into meaningful, actionable insights.
Meet the Allotype BioDiscovery Team
